NCT05667688View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics Study of LBS-008 in Healthy Volunteers Aged 50-85

PHASE1CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

November 28, 2022

Primary Completion Date

January 4, 2023

Study Completion Date

January 18, 2023

Conditions

Healthy VolunteerDry Age-related Macular Degeneration

Interventions

DRUG

Tinlarebant (LBS-008)

A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.

Trial Locations (1)

Unknown

Nucleus Network, Melbourne

Sponsors

Collaborators (1)

Belite Bio, Inc

All Listed Sponsors

collaborator

Belite Bio, Inc

INDUSTRY

lead

RBP4 Pty Ltd

INDUSTRY